(VERA) Vera Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.466m USD | Total Return: 73.4% in 12m
Avg Turnover: 36.8M
Warnings
Interest Coverage Ratio -32.2 is critical
Altman Z'' -10.16 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
Vera Therapeutics, Inc. (VERA) is a clinical-stage biotechnology company headquartered in Brisbane, California, specializing in treatments for immunological and autoimmune kidney diseases. Its lead product candidate, atacicept, is a self-administered fusion protein targeting BAFF and APRIL ligands, currently under evaluation for the treatment of IgAN. The company’s pipeline also includes MAU868 for BK viremia and VT-109 for B cell-mediated autoimmune disorders.
The biotechnology sector often operates on a high-risk, high-reward model where clinical trial outcomes and regulatory milestones serve as primary catalysts for valuation. Vera Therapeutics utilizes a targeted biologics approach, focusing on dual-inhibitor molecules to address the underlying drivers of chronic inflammatory conditions rather than just managing symptoms.
Further analysis of recent clinical data and market positioning is available at ValueRay for those conducting deeper due diligence.
- Atacicept Phase 3 clinical trial results for IgAN determine long-term valuation
- FDA approval timeline for BAFF and APRIL dual-inhibitor therapies
- Competitive landscape in the IgAN market impacts potential peak market share
- Cash runway and future equity financing needs for commercialization efforts
- Regulatory milestones for MAU868 monoclonal antibody in BK viremia treatment
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.54 > 0.02 and ΔFCF/TA -25.49 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.47 > 3% & CFO -293.2m > Net Income -369.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.5m) vs 12m ago 12.26% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -32.25 > 6 (EBITDA TTM -362.8m / Interest Expense TTM 11.3m) |
| A: 0.92 (Total Current Assets 615.8m - Total Current Liabilities 45.1m) / Total Assets 621.7m |
| B: -1.42 (Retained Earnings -881.9m / Total Assets 621.7m) |
| C: -0.59 (EBIT TTM -363.9m / Avg Total Assets 616.0m) |
| D: -7.23 (Book Value of Equity -882.0m / Total Liabilities 122.0m) |
| Altman-Z'' = -10.16 = D |
As of May 24, 2026, the stock is trading at USD 34.35 with a total of 508,892 shares traded.
Over the past week, the price has changed by -8.79%,
over one month by -15.47%,
over three months by -19.07% and
over the past year by +73.41%.
Vera Therapeutics has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy VERA.
- StrongBuy: 9
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 78.3 | 127.9% |
Revenue TTM = 0.0 USD
EBIT TTM = -363.9m USD
EBITDA TTM = -362.8m USD
Long Term Debt = 74.8m USD (from longTermDebt, last fiscal year)
Short Term Debt = 549k USD (from shortTermDebt, last fiscal year)
Debt = 77.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 2.47m
Net Debt = -497.2m USD (calculated: Debt 77.5m - CCE 574.7m)
Enterprise Value = 1.97b USD (2.47b + Debt 77.5m - CCE 574.7m)
Interest Coverage Ratio = -32.25 (Ebit TTM -363.9m / Interest Expense TTM 11.3m)
EV/FCF = -5.81x (Enterprise Value 1.97b / FCF TTM -338.7m)
FCF Yield = -17.21% (FCF TTM -338.7m / Enterprise Value 1.97b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 256k) / Revenue TTM)
Tobins Q-Ratio = 3.17 (Enterprise Value 1.97b / Total Assets 621.7m)
Interest Expense / Debt = 14.56% (Interest Expense 11.3m / Debt 77.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -287.4m (EBIT -363.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.43 (Total Current Assets 615.8m / Total Current Liabilities 59.1m)
Debt / Equity = 0.16 (Debt 77.5m / totalStockholderEquity, last quarter 499.7m)
Debt / EBITDA = 1.37 (negative EBITDA) (Net Debt -497.2m / EBITDA -362.8m)
Debt / FCF = 1.47 (negative FCF - burning cash) (Net Debt -497.2m / FCF TTM -338.7m)
Total Stockholder Equity = 492.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.90% (Net Income -369.0m / Total Assets 621.7m)
RoE = -26.84% (Net Income TTM -369.0m / Total Stockholder Equity 1.37b)
RoCE = -25.10% (EBIT -363.9m / Capital Employed (Equity 1.37b + L.T.Debt 74.8m))
RoIC = -80.61% (negative operating profit) (NOPAT -287.4m / Invested Capital 356.6m)
WACC = 11.35% (E(2.47b)/V(2.54b) * Re(11.35%) + D(77.5m)/V(2.54b) * Rd(14.56%) * (1-Tc(0.21)))
Discount Rate = 11.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 23.50%
[DCF] Fair Price = unknown (Cash Flow -338.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -3.20 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.75 | Chg30d=-22.44% | Revisions=-25% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-1.60 | Chg30d=-15.09% | Revisions=-43% | Analysts=5
EPS current Year (2026-12-31): EPS=-6.15 | Chg30d=-17.00% | Revisions=-64% | GrowthEPS=-32.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.56 | Chg30d=-17.00% | Revisions=-45% | GrowthEPS=+42.1% | GrowthRev=+481.2%
[Analyst] Revisions Ratio: -64%